In a small trial involving children with progressive high-grade gliomas, direct infusions of a genetically engineered strain of herpes simplex virus elicited responses in 11 of 12 recipients. The therapy also led to more than a doubling in average patient survival compared with historical expectations.

You do not currently have access to this content.